

Biobanking from a global perspective

Karin Gedda, AstraZeneca R&D Gothenburg

Nordic Biobank Conference 2022




Conflict of interest

No disclosures

September 6-8, 2022 • #nordicbiobank2022 • nbc.biobanksverige.se



Agenda



Introduction

AstraZeneca

AZ Biobank

Future strategy




AstraZeneca



Global, science-led, patient-focused biopharmaceutical company











Therapy area focus

- Oncology ۰
- Cardiovascular, ۰ Renal & Metabolism
- **Respiratory &** ۰ Immunology
- Vaccines & Immune • Therapies
- Rare Disease






Commitment to people, society and the planet



Global strength, with balanced presence across regions



Our strategic priorities



Deliver growth and therapy area leadership






Accelerate innovative science

Be a great place to work



Focus on main therapy areas and across key platforms





Strategic R&D sites close to global bioscience clusters





AstraZeneca in Gothenburg

Gothenburg has a unique culture of **collaboration and open innovation**, supporting all our main therapy areas throughout the entire life cycle of our medicines.



Supporting the entire life cycle of medicines: drug discovery, advanced drug delivery, medical device development, manufacturing for clinical trials.



Gothenburg

~2,800 employees of 70+ nationalities, including 600 PhD researchers and 30 professors. 57.9% of our line managers in Gothenburg are women.




Reduced the site's carbon dioxide emissions by 99% since 2015 with a clear vision to further reduce our carbon footprint.




AZ Biobank



PMB – Biosamples structure



HBS Governance Framework



HBS Definition

Globally AstraZeneca defines HBS as biological material sourced or derived directly from a living or deceased human being, which consists of or includes human cells. This includes human organs, cells, tissues and body fluids.

AstraZeneca additionally includes genetic material within this definition, due to potential identification of an individual through generated data.

*Additional Local Regulations & Legislations will apply

SHTA Human Tissue Authorit, ORDEM E PRO

New or changing HBS legislation across the world is a challenge for a global organisation.

Some examples of legislation on HBS that affects our business for Biobanking:

- Swedish Act on Biobanks:
 - no long-term storage of samples outside of Sweden.
- UK Human Tissue Act (2004):
 - Track all samples to 'Cell level'

Some examples of legislation on HBS that affects our business for sample collection, storage & use:

- Brazil:
 - Storage of HBS after study closure is strictly regulated
- China:
 - Human Genetic Resources Act of China (HGRAC or HGR for short)
 - Import and export of HBS and derived data is heavily regulated

General Data Protection Regulation



• Personal Data is any information which directly or indirectly can be used to identify a living person.

• The law aim to protect the personal integrity against violation when Personal Data is:

- Collected
- Used
- Retained
- Disposed

AZ Biobank – why are we here?

To efficiently collate, store and distribute high quality HBS, in full compliance with ethical and legal standards, to support projects and science.

> One sustainable and visible Human Biological Samples (HBS) library to drive projects and science while ensuring ethical sample storage and use.

One Biobank model

Sustainable biobank

- Keep the 'correct' samples useable
- Increased use of available samples
- Environmental impact
 - Storage
 - shipments
- Biobank capacity

One sample catalogue

- A single view of the sample library
- All samples visible
- Appropriate description of the samples

Governance and biobank operations

- Governance oversight for all HBS activities
- One global biobank including all samples coming into AZ
- Samples to come in to biobank and to be checked out to scientists

Biobank Facilities

- Designed to meet the needs of the Biobank
- Capabilities include Ambient and Cryogenic Storage
- Energy efficient, environmentally sustainable Ultra Low Temperature units (ULTs)
- Larger Storage capacity/per sqft of floor space – reduced footprint





Organizational winners:

- AstraZeneca
- The U.S. National Institutes of Health
- The Whitehead Institute and the Massachusetts
 Institute of Technology

Winning Streak Award:

· University of Illinois Urbana-Champaign

Individual laboratory winners:

- The Janssen Biotherapeutics (JBIO) Lab at Janssen Pharmaceuticals in La Jolla, CA
- The Laboratory of Cell Biology at the Center for Cancer Research of the National Cancer Institute at the National Institutes of Health
- The Learning and Research Laboratory at the University of Bristol









Global site biobanks support





✓	
✓	-
✓	-
<	

Quick access to clinical trial and commercial samples

Right sample at the right time

Global visibility of all HBS Ensure correct data comes with the samples and tracked


Chain of custody–compliance oversight

Usage tracked


Usage restrictions tracked



AstraZeneca R&D AZ Biobank sites







What's in our storage?

Blood, serum, plasma, CSF, urine, tissue, primary cells, tissue blocks, slides, biopsies.. From ambient to -150 (LN2) storage



23

A variety of samples types in a variety of shapes and forms



All HBS samples needs to:



Be from an approved source only

Have appropriate consent for collection, storage & use

Have an owner to approve all collection & use



Only be used in accordance with the consent



Be uniquely identified and labelled to protect the donor identity



Be assigned to a Biobank



Have a custodian

Have a chain of custody




Be collected and processed correctly



Have optimal conditions for storage and transit




Sourcing of HBS for Research



What about the future?




We are only just beginning to explore the wealth of potential drug targets for human disease



We are investing in multiple approaches to help identify and validate the 'Right Targets'

Genomics



Functional Genomics

Future Biobank

- Key future role for biobank
 - Use of human samples underpin new strategy
 - Ensure every patient sample counts

- Next generation biobank IT solution
 - Search in annotated catalogue
 - Enhance use of available samples



- State-of-the-art storage
 - Automated storage solution
 - Rapid omics-ready access to samples
 - Best-in-class freezers



Challenges...





Changes in laws and regulations – staying compliant

Storage solutions – manage oversight

Increased use of samples – efficient processes for compliance checks and retrieval of samples

Sustainable sample collection

Making our science sustainable

Access to healthcare


Health is at the heart of our business



The health of the planet impacts all life

Ethics & transparency

Equality and prosperity for all fosters healthy societies





Where we are committed to driving positive change

Access to healthcare




Increasing access to lifesaving treatments

Promoting **prevention**

Strengthening the resilience and sustainability of healthcare systems

Environmental protection



Proactively managing our **environmental impact**

Investing in **nature and biodiversity**


Ethics and transparency

Ensuring behaviour across our organisation and value chain that is:

Ethical and Open

Safe and Inclusive





Sustainability in the Biobank

- Updated freezer park and better use of freezer space
 - Reduce use of dry ice manage shipments
 - Long term storage as applicable
 - Visit poster P02 for more details!





Thank you!

Karin Gedda

Senior Director, Head of Global Biobank

Precision Medicine and Biosamples, Onc R&D

AstraZeneca R&D Gothenburg

karin.gedda@astrazeneca.com

September 6-8, 2022 • #nordicbiobank2022 • nbc.biobanksverige.se